Schering Sees No Impact From Rx Imports; Portfolio Not Attractive To "Parallel Traders"
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering still believes importation is the wrong approach to lowering U.S. drug costs. "Parallel importers" have little incentive to pass on savings to patients, and FDA cannot adequately regulate the supply chain, CEO Fred Hassan says.
You may also be interested in...
FDA Employees’ Outside Activities Will Receive Scrutiny By Center Directors
Activities had been approved at lower levels, but the interim policy – issued following questions about behavior of NIH scientists – escalates the oversight. All outside activities by FDA employees will be reviewed as part of the development of a final policy.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?
US FDA Advisory Panels May Look Different Across Centers, Despite Efforts To Standardize Process
As FDA is readying to go back to in-person advisory committee meetings this fall, the centers have different ideas about how to use their expert panels.